Metformin in Reproductive Biology
Initially produced in Europe in 1958, metformin is still one of the most widely prescribed drugs to treat type II diabetes and other comorbidities associated with insulin resistance. Metformin has been shown to improve fertility outcomes in females with insulin resistance associated with polycystic...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-11-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fendo.2018.00675/full |
| _version_ | 1818324363637686272 |
|---|---|
| author | Melanie Faure Michael J. Bertoldo Rita Khoueiry Alice Bongrani François Brion Cecilia Giulivi Cecilia Giulivi Joelle Dupont Pascal Froment |
| author_facet | Melanie Faure Michael J. Bertoldo Rita Khoueiry Alice Bongrani François Brion Cecilia Giulivi Cecilia Giulivi Joelle Dupont Pascal Froment |
| author_sort | Melanie Faure |
| collection | DOAJ |
| description | Initially produced in Europe in 1958, metformin is still one of the most widely prescribed drugs to treat type II diabetes and other comorbidities associated with insulin resistance. Metformin has been shown to improve fertility outcomes in females with insulin resistance associated with polycystic ovary syndrome (PCOS) and in obese males with reduced fertility. Metformin treatment reinstates menstrual cyclicity, decreases the incidence of cesareans, and limits the number of premature births. Notably, metformin reduces steroid levels in conditions associated with hyperandrogenism (e.g., PCOS and precocious puberty) in females and improves fertility of adult men with metabolic syndrome through increased testosterone production. While the therapeutical use of metformin is considered to be safe, in the last 10 years some epidemiological studies have described phenotypic differences after prenatal exposure to metformin. The goals of this review are to briefly summarize the current knowledge on metformin focusing on its effects on the female and male reproductive organs, safety concerns, including the potential for modulating fetal imprinting via epigenetics. |
| first_indexed | 2024-12-13T11:27:24Z |
| format | Article |
| id | doaj.art-0c4f2607af9249cb848a95b018b42a40 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-13T11:27:24Z |
| publishDate | 2018-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-0c4f2607af9249cb848a95b018b42a402022-12-21T23:48:08ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922018-11-01910.3389/fendo.2018.00675393399Metformin in Reproductive BiologyMelanie Faure0Michael J. Bertoldo1Rita Khoueiry2Alice Bongrani3François Brion4Cecilia Giulivi5Cecilia Giulivi6Joelle Dupont7Pascal Froment8Unité de Physiologie de la Reproduction et des Comportements, Centre Val de Loire, Institut National de la Recherche Agronomique, UMR85, Nouzilly, FranceDiscipline of Obstetrics and Gynaecology, School of Women's and Children's Health, University of New South Wales, Sydney, NSW, AustraliaDepartment of Development and Regeneration, Stem Cell Institute, KU Leuven, Leuven, BelgiumUnité de Physiologie de la Reproduction et des Comportements, Centre Val de Loire, Institut National de la Recherche Agronomique, UMR85, Nouzilly, FranceINERIS, Direction des Risques Chroniques, Pole VIVA, Unite d'ecotoxicologie in vitro et in vivo, BP2, Verneuil-en-Halatte, FranceDepartment of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, Davis, CA, United StatesMedical Investigations of Neurodevelopmental Disorders Institute, University of California, Davis, Davis, CA, United StatesUnité de Physiologie de la Reproduction et des Comportements, Centre Val de Loire, Institut National de la Recherche Agronomique, UMR85, Nouzilly, FranceUnité de Physiologie de la Reproduction et des Comportements, Centre Val de Loire, Institut National de la Recherche Agronomique, UMR85, Nouzilly, FranceInitially produced in Europe in 1958, metformin is still one of the most widely prescribed drugs to treat type II diabetes and other comorbidities associated with insulin resistance. Metformin has been shown to improve fertility outcomes in females with insulin resistance associated with polycystic ovary syndrome (PCOS) and in obese males with reduced fertility. Metformin treatment reinstates menstrual cyclicity, decreases the incidence of cesareans, and limits the number of premature births. Notably, metformin reduces steroid levels in conditions associated with hyperandrogenism (e.g., PCOS and precocious puberty) in females and improves fertility of adult men with metabolic syndrome through increased testosterone production. While the therapeutical use of metformin is considered to be safe, in the last 10 years some epidemiological studies have described phenotypic differences after prenatal exposure to metformin. The goals of this review are to briefly summarize the current knowledge on metformin focusing on its effects on the female and male reproductive organs, safety concerns, including the potential for modulating fetal imprinting via epigenetics.https://www.frontiersin.org/article/10.3389/fendo.2018.00675/fulltestisovarymetforminoocytesspermatogenesis |
| spellingShingle | Melanie Faure Michael J. Bertoldo Rita Khoueiry Alice Bongrani François Brion Cecilia Giulivi Cecilia Giulivi Joelle Dupont Pascal Froment Metformin in Reproductive Biology Frontiers in Endocrinology testis ovary metformin oocytes spermatogenesis |
| title | Metformin in Reproductive Biology |
| title_full | Metformin in Reproductive Biology |
| title_fullStr | Metformin in Reproductive Biology |
| title_full_unstemmed | Metformin in Reproductive Biology |
| title_short | Metformin in Reproductive Biology |
| title_sort | metformin in reproductive biology |
| topic | testis ovary metformin oocytes spermatogenesis |
| url | https://www.frontiersin.org/article/10.3389/fendo.2018.00675/full |
| work_keys_str_mv | AT melaniefaure metformininreproductivebiology AT michaeljbertoldo metformininreproductivebiology AT ritakhoueiry metformininreproductivebiology AT alicebongrani metformininreproductivebiology AT francoisbrion metformininreproductivebiology AT ceciliagiulivi metformininreproductivebiology AT ceciliagiulivi metformininreproductivebiology AT joelledupont metformininreproductivebiology AT pascalfroment metformininreproductivebiology |